Nysfungin Pharma Grade API is a fermentation-derived polyene macrolide antifungal complex obtained from selected strains of Streptomyces noursei. The dried substance is supplied as a yellow to light brown hygroscopic powder intended for formulation into oral solid dosage forms—tablets, capsules, granules—and, where regional registrations permit, injectable presentations following aseptic or lipid-associated processing. The product is designated by route-specific grade rather than a universal model number: oral solid-dose grade for tablet, capsule, and granule operations, and injectable grade for parenteral or lipid-complex presentations. Supplier lot-specific certificates of analysis control the actual grade code.

The principal active component is nystatin A₁, with a molecular formula of C₄₇H₇₅NO₁₇ and a molecular weight of 926.1 g/mol, accompanied by nystatin A₂ and A₃ structural analogues. The complex is characterized by tetraene ultraviolet absorption maxima at 230, 291, 305, and 319 nm. Minimum potency is 4400 IU/mg on the dried basis under the USP/NF nystatin monograph; commercial certificates of analysis frequently report release potency above the minimum, with exact values varying by fermentation lot.

Which Release Specifications and Pharmacopoeial Methods Govern Nysfungin API?

Pharmacopoeial alignment follows the USP/NF nystatin monograph, Ph. Eur. 01/2008:1147, and the corresponding Chinese Pharmacopoeia monograph where Nysfungin is recognized as a nystatin-type complex. Identification is confirmed by infrared absorption spectrophotometry and ultraviolet absorption spectrophotometry. Potency is assigned by HPLC or microbiological assay against the appropriate reference standard. Loss on drying is controlled to ≤ 5.0%. The pH of a 3% aqueous suspension is controlled between 4.5 and 7.0. Residue on ignition is limited to ≤ 0.2%. Residual solvents comply with ICH Q3C. Injectable-grade material additionally requires bacterial endotoxin and sterility data when the final dosage form is parenteral.

Tablet and capsule operations require strict humidity control because the API is hygroscopic and light-sensitive. Direct compression is generally problematic due to poor flow and low bulk density; when direct compression is attempted, pre-drying at 25 °C and ≤ 35% RH is required, and colloidal silicon dioxide at 0.5–1.0% w/w is added to improve flow. Exposure above 60% RH leads to particle agglomeration, caking in feed hoppers, and weight variation during compression. Wet granulation is the more robust route. The API is dispersed with pregelatinized starch and microcrystalline cellulose, granulated with aqueous or hydroalcoholic binder, and dried in fluid-bed equipment at an inlet air temperature of 45–60 °C and a product temperature of 28–32 °C. High-shear mixing should be limited to 3–5 min after binder addition to avoid overheated granule formation and potency loss.

For capsule filling, the milled blend is processed on dosator or tamping-pin capsule machines. Lubrication with magnesium stearate is held to 1.0–2.0% w/w and blended for 3–5 min in a tumble blender; extended blending can reduce disintegration rate and decrease antifungal dissolution. Granule formation for reconstituted oral suspension is performed by fluid-bed top-spray granulation with binder viscosity maintained at 5–15 mPa·s and spray rate adjusted to produce granules with a median particle size of 150–300 µm. Oversize material is returned to a cone mill fitted with a 0.8 mm screen. Published data for this specific configuration is limited, so processing ranges should be qualified on production-scale equipment.

Fermentation-Derived Polyene Macrolide Chemistry and Solid-Dosage Constraints

The antifungal activity of Nysfungin arises from direct binding to ergosterol in the fungal cell membrane, leading to transmembrane pore formation, leakage of potassium and other intracellular cations, and cell death. The tetraene chromophore is responsible for the characteristic UV absorption and for the sensitivity of the API to light and oxygen. The powder should be stored in sealed, light-resistant containers under nitrogen or vacuum. Prolonged storage at elevated temperature accelerates oxidative degradation of the polyene double-bond system; therefore, warehouse temperature is normally controlled below 25 °C. The API is practically insoluble in water and exhibits negligible systemic absorption from the gastrointestinal tract. This property confines the oral dosage forms to local action in the oral cavity, esophagus, and intestinal lumen.

In tablet and capsule production, the principal processing bottlenecks are sticking and picking on rotary tablet presses due to moisture uptake, as well as dose non-uniformity from poor flow. Steel tooling with chromium nitride coating is preferred to reduce sticking; however, proof of scale is required because the polyene complex can interact with metal surfaces. Tablet hardness is typically maintained at 6–10 kp for immediate-release oral tablets, and disintegration is specified in purified water at 37 °C using apparatus conforming to Ph. Eur. 2.9.1 or USP 701. Capsule products are tested for dissolution according to USP 2040 or a qualified dissolution method; because of low aqueous solubility, dissolution media often contain a surfactant such as sodium lauryl sulfate at 0.1–0.5% w/v.

Granule presentations intended for oral suspension require the inclusion of suspending agents, buffering agents, and preservatives. The API is blended with sucrose or sorbitol, sodium carboxymethylcellulose, and sodium phosphate buffer. The dry granules are filled into aluminum foil pouches or amber glass bottles to reduce light exposure. The reconstituted suspension should be used within the period specified by the stability data because the polyene complex degrades more rapidly in aqueous media. Storage of the finished oral suspension is generally limited to 7–14 days under refrigeration, but this period must be confirmed with product-specific stability studies.

When Injectable-Grade Nysfungin Is Demanded, Which Additional Controls Become Binding?

Because Nysfungin is practically insoluble in water and poorly absorbed systemically, a conventional parenteral solution is not feasible. An injectable presentation, if registered, would require lipid association, phospholipid complexation, or surfactant-solubilized delivery. In such systems, the API must be processed under nitrogen or vacuum to limit oxidative degradation. The final lipid dispersion is homogenized under high pressure and passed through a 0.22 µm sterilizing-grade membrane. The injectable-grade specification adds bacterial endotoxin testing according to Ph. Eur. 2.6.14 and particulate matter control according to Ph. Eur. 2.9.19 or USP 788. Sterility of the finished injectable is governed by Ph. Eur. 2.6.1 or USP 71. Container closure integrity testing is required under USP 1207 or a qualified vacuum decay method.

No harmonized parenteral monograph currently exists for Nysfungin, and major pharmacopoeias describe nystatin-type products as orally or topically administered agents. Therefore, parenteral development requires the sponsoring manufacturer to establish drug-product-specific safety data, bioequivalence data, and stability data. The API supplier can provide endotoxin-controlled material, but the final injectable formulation is a non-compendial dosage form. Injectable Nysfungin should not be assumed to be interchangeable with conventional parenteral amphotericin B, because the two polyene APIs differ in unsaturation class, systemic exposure, and toxicity profile.

Comparative Antifungal Spectrum and Functional Differences from Other Polyene and Azole APIs

Nysfungin differs from amphotericin B in the polyene subclass and the primary route of use. Nysfungin is a tetraene macrolide with negligible oral absorption, used for local and gastrointestinal candidiasis. Amphotericin B is a heptaene macrolide with intravenous activity against systemic mycoses but with dose-dependent nephrotoxicity and infusion-related reactions. Compared with azole antifungals such as fluconazole, the polyene mechanism is direct ergosterol binding and membrane pore formation, which can be fungicidal. Azoles inhibit lanosterol 14α-demethylase and are generally fungistatic against susceptible organisms. The difference in mechanism has practical consequences for resistance. Azole resistance is common and arises through ERG11 mutations, target overexpression, or efflux pump upregulation. Polyene resistance is less common and is associated with ERG3 or ERG6 mutations that alter membrane sterol composition.

Nysfungin and Nystatin are both nystatin-type fermentation complexes, and in regulatory practice they may be considered interchangeable names for the same polyene complex. Where regional monographs distinguish them, the difference is primarily the fermentation strain selection and the allowable ratio of nystatin A₁, A₂, and A₃ components. This distinction can affect the impurity profile and the UV absorption ratio, but both APIs are used for the same class of oral and mucosal candidiasis. The receiving pharmaceutical manufacturer should map the supplier-specific component ratio to the intended dissolution and potency acceptance criteria during technology transfer.

For oral tablet and capsule formulations, the most common unitages are 100,000, 500,000, and 1,000,000 IU per dosage unit, although regional approved strengths may vary. The product is indicated for non-invasive candidal infections of the gastrointestinal tract and mucocutaneous surfaces; it is not used for systemic candidiasis because of negligible oral absorption and the absence of a conventional parenteral solution. The injectable grade, where applicable, is subject to additional aseptic-processing and endotoxin controls and is not automatically bioequivalent to oral presentations. The API is incompatible with strong oxidizing agents, and prolonged contact with aqueous media at elevated temperature accelerates degradation of the tetraene chromophore.